CARMA Therapeutics Inc , a biotechnology company developing cellular immunotherapies co-founded by the University of Pennsylvania Penn announced today that it has closed an initial financing The financing was co-led by AbbVie Ventures and HealthCap with participation by Grazia Equity and IP Group Inc CARMA Therapeutics is building a pipeline of cancer programs using its proprietary CARMA platform combining chimeric antigen receptor targeting with macrophages to tackle solid tumors The proceeds will be used primarily to advance the development of its first product CARMA-0508 an adoptive cellular immunotherapy using chimeric antigen receptor macrophages CARMA for the treatment of metastatic solid tumors Specific terms of the financing transaction were not disclosed
CARMA Therapeutics is being built upon innovative technology from the Center for Cellular Immunotherapies at the University of Pennsylvania and was spun out from the laboratory of Saar Gill MD PhD assistant professor of Hematology Oncology in the Perelman School of Medicine at the University of Pennsylvania We hypothesized early on that focusing on different effector cells other than T cells might be more effective in trying to tackle solid tumors which has been a challenge for T cell therapies The innate biology drove us to try macrophages says Dr Gill co-founder of CARMA Therapeutics who conducts bench and clinical research on chimeric antigen receptor CAR T cells and now on CAR macrophages
Macrophages can engulf and kill cells through the process of phagocytosis By genetically engineering these cells with CARs we can specifically direct them to tumor cells such as ovarian cancer cells says co-founder Michael Klichinsky PharmD a PhD candidate in the Department of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania Our pre-clinical data support our hypothesis and show targeted selective and effective killing of solid tumor cells by CARMA In addition we expect that CAR macrophages will prime a T cell immune response against the tumor ”
We are extremely pleased with the incubation investment syndicate led by an excellent balance of high profile investors AbbVie Ventures the strategic venture investing arm of AbbVie and one of the most active early-stage corporate venture groups in biotech and HealthCap one of the largest life sciences investors in Europe with deep experience in oncology therapeutics The participation of early-stage investor IP Group Inc continues its strong commercialization partnership with the Penn UPstart program and Grazia Equity brings their experience in working with companies from their initiation stages all the way to IPO said Dora Mitchell PhD Director of the UPstart program at PCI Ventures a division of the Penn Center for Innovation PCI which launched the company in keeping with the University of Pennsylvania commitment to innovation and commercialization of Penn inventions
Cell therapy oncology products in clinical development have shown promise in the treatment of hematological cancers The next frontier in immuno-oncology is in solid tumors says Bruce Peacock a veteran of Philadelphia biotech successes Centocor and Cephalon and Executive Chairman of CARMA Therapeutics When I first met the founding team I was impressed by the promising technology developed by Drs Gill and Klichinsky and delighted to work with Dr Mitchell in building CARMA Dora’s leadership in creating CARMA is a great example of the University of Pennsylvania commitment to move its powerful research into companies and products which will create jobs and benefit patients I believe that CARMA Therapeutics has the potential to be the next great Philadelphia biotech and am honored to help build that ”
To bring CARMA to its full potential the Board is looking to expand the team with the recruitment of a CEO as its top priority
About CARMA Therapeutics Inc
CARMA TherapeuticsSM is a biotechnology company founded in 2016 to bring the power of adoptive cellular immunotherapy to solid tumor patients through a novel platform using chimeric antigen receptor macrophages CARMA The company’s proprietary technology was developed at the Center for Cellular Immunotherapy at the Perelman School of Medicine at the University of Pennsylvania CARMA TherapeuticsSM is headquartered in Philadelphia PA For more information visit www carmatherapeutics com
About PCI Ventures
PCI Ventures a division of the Penn Center for Innovation manages a portfolio of emerging companies based on University of Pennsylvania inventions Through a unique hands-on company building model called UPstart PCI Ventures partners with faculty and staff to turn their ideas into commercial products for the benefit of the University the Philadelphia economy and society For more information www pci upenn edu/pciventures
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/CARMA%20Therapeutics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
